AstraZeneca Pharma India and Sun Pharmaceutical Industries have formed an exclusive brand partnership to promote and distribute SZC for hyperkalaemia treatment under separate brands
The deal is expected to be announced at the White House on Friday, said the people, who spoke on condition of anonymity because the plans are not yet public
The decline in the company's share price came as its shares traded ex-date following the announcement of a ₹32 per share dividend
AstraZeneca Pharma shares rose after the company received regulatory approval to expand the use of its cancer drug Imfinzi (Durvalumab) in India.
Global bio-pharmaceutical company AstraZeneca has established its state-of-the-art Global Hub in Bengaluru investing Rs 166 crore to focus on development of AI-powered healthcare solutions, a top official said on Thursday. This marks the second major investment by AstraZeneca in July 2024 after it announced expansion of its Global Innovation and Technology Centre in Chennai with an outlay of Rs 250 crore. The new facility in Bengaluru is designed to accommodate nearly 1,300 employees including 400 new jobs. It will support the company's capabilities in AI-powered innovation across Research and Development, global business services, Information Technology and digital health operations, among others. The Global Hub in Bengaluru is dedicated to Research and Development, Global Business Services, Information Technology while the Global Innovation and Technology Centre in Chennai serves as a strategic hub for IT, Global Business Services. Following the expansion of the facility, the ...